Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
BACKGROUND
Angiotensin II regulates the production of adipokines. The objective was to study the effect of treatment with irbesartan versus olmesartan in obese hypertensive women.


METHODS
A sample of 34 obese hypertensive women was analyzed in a prospective way with a randomized trial. Patients were randomized to irbesartan (300 mg/day) or olmesartan (40 mg/day) for 3 months. Weight, body mass index, blood pressure, basal glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, HOMA and visfatin were determined at basal time and after 3 months of treatment.


RESULTS
Thirty four patients gave informed consent and were enrolled in the study. A significative decrease in systolic and diastolic blood pressures was reached without changes in weight. Patients treated with olmesartan had a significative decrease of total cholesterol, LDL cholesterol, insulin, HOMA and visfatin levels. Decrease in total cholesterol and LDL cholesterol was similar with both angiotensin receptor blockers. Decrease in insulin (2.28 +/- 2.77 vs 0.66 +/- 4.4 mUI/L: p < 0.05), HOMA (0.69 +/- 1.1 vs 0.48 +/- 1.6 units: p < 0.05) and visfatin (5.16 +/- 13 vs 1.85 +/- 9.1 ng/ml: p < 0.05) levels was higher in olmesartan than irbesartan group.


CONCLUSIONS
The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels.
Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega. RD-056/0013 RETICEF, University of Valladolid, Valladolid, Spain. dadluis@yahoo.es
D A
DA
De Luis
R
R
Conde
M
M
Gonzalez Sagrado
R
R
Aller
O
O
Izaola
J L
JL
Perez Castrillon
E
E
Romero
M J
MJ
Castro
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D000077405:Irbesartan; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D011446:Prospective Studies; D013030:Spain; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D015415:Biomarkers; D001713:Biphenyl Compounds; D001786:Blood Glucose; D016207:Cytokines; D007093:Imidazoles; D007328:Insulin; D013777:Tetrazoles; D014280:Triglycerides; C437965:olmesartan; D002784:Cholesterol; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human; D000077405:Irbesartan